Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iloperidone - Vanda Pharmaceuticals

Drug Profile

Iloperidone - Vanda Pharmaceuticals

Alternative Names: Fanapt; Fanaptum; Fiapta; HP-873; ILO-522; VYV-683; Zomaril

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer MegaPharm Ltd; Novartis; PROBIOMED; University of Colorado at Denver; Vanda Pharmaceuticals
  • Class Antipsychotics; Isoxazoles; Mood stabilisers; Piperidines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Schizophrenia
  • Preregistration Bipolar disorders
  • Phase II Post-traumatic stress disorders; Psychotic disorders
  • No development reported Unspecified

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for phase-I development in Schizophrenia in USA (Injection, Controlled release)
  • 08 Nov 2023 Preregistration for Bipolar disorders (In the elderly, In adults) in USA (PO)
  • 08 Nov 2023 FDA assigns PDUFA action date of 02/04/2024 for iloperidone (Fanapt®) for Bipolar disorder
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top